J
Julie Irving
Researcher at Newcastle University
Publications - 142
Citations - 6731
Julie Irving is an academic researcher from Newcastle University. The author has contributed to research in topics: Leukemia & Medicine. The author has an hindex of 40, co-authored 129 publications receiving 5962 citations. Previous affiliations of Julie Irving include McGill University & Vancouver General Hospital.
Papers
More filters
Journal ArticleDOI
Cultivating mindfulness in health care professionals: A review of empirical studies of mindfulness-based stress reduction (MBSR)
TL;DR: This review will examine the potential benefits of mindfulness-based stress reduction (MBSR) programs aimed at enhancing well-being and coping with stress in this population of health care professionals.
Journal ArticleDOI
Deregulated expression of cytokine receptor gene, CRLF2 , is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
Lisa J. Russell,Melania Capasso,Inga Vater,Takashi Akasaka,Olivier Bernard,María José Calasanz,Thiruppavaii Chandrasekaran,Elise Chapiro,S Gesk,Mike Griffiths,David S. Guttery,Claudia Haferlach,Lana Harder,Olaf Heidenreich,Julie Irving,Lyndal Kearney,Florence Nguyen-Khac,Lee Machado,Lynne Minto,Aneela Majid,Anthony V. Moorman,Heather Morrison,Vikki Rand,Jonathan C. Strefford,Claire Schwab,Holger Tönnies,Martin J. S. Dyer,Reiner Siebert,Christine J. Harrison +28 more
TL;DR: Overexpression of CRLF2 was associated with activation of the JAK-STAT pathway in cell lines and transduced primary B-cell progenitors, sustaining their proliferation and indicating a causal role of C RLF2 overexpression in lymphoid transformation.
Journal ArticleDOI
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.
Elli Papaemmanuil,Fay J. Hosking,Jayaram Vijayakrishnan,Amy Price,Bianca Olver,Eammon Sheridan,Sally E. Kinsey,Tracy Lightfoot,Eve Roman,Julie Irving,James M. Allan,Ian Tomlinson,Malcolm Taylor,Mel Greaves,Richard S. Houlston +14 more
TL;DR: Data show that common low-penetrance susceptibility alleles contribute to the risk of developing childhood ALL and provide new insight into disease causation of this specific hematological cancer.
Journal ArticleDOI
In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties
Christoph le Viseur,Marc Hotfilder,Simon Bomken,Kerrie Wilson,Silja Röttgers,André Schrauder,Annegret Rosemann,Julie Irving,Ronald W. Stam,Leonard D. Shultz,Jochen Harbott,Heribert Jürgens,Martin Schrappe,Rob Pieters,Josef Vormoor +14 more
TL;DR: Surprisingly, blasts representative of all of the different maturational stages were able to reconstitute and reestablish the complete leukemic phenotype in vivo and inform a model for leukemia-propagating stem cells in childhood ALL.
Journal ArticleDOI
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk
Amy L. Sherborne,Fay J. Hosking,Rashmi B. Prasad,Rajesh Kumar,Rolf Koehler,Jayaram Vijayakrishnan,Elli Papaemmanuil,Claus R. Bartram,Martin Stanulla,Martin Schrappe,Andreas Gast,Sara E. Dobbins,Yussanne Ma,Eamonn Sheridan,Malcolm Taylor,Sally E. Kinsey,T Lightfoot,Eve Roman,Julie Irving,James M. Allan,Anthony V. Moorman,Christine J. Harrison,Ian Tomlinson,Sue Richards,Martin Zimmermann,Csaba Szalai,Ágnes F. Semsei,Dániel J. Erdélyi,Maja Krajinovic,Daniel Sinnett,Jasmine Healy,Anna Gonzalez Neira,Norihiko Kawamata,Seishi Ogawa,H. Phillip Koeffler,Kari Hemminki,Mel Greaves,Richard S. Houlston +37 more
TL;DR: Common variation at 9p21.3 (rs3731217, intron 1 of CDKN2A) influences acute lymphoblastic leukemia risk (odds ratio = 0.71, P = 3.01 × 10−11), irrespective of cell lineage.